GlassScriptPhysician profile
Ellias N Maroun
NPI 1164677373
$2,836.77
in general payments reported to CMS, 2019-2025
14 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $320 · 2021: $128 · 2022: $675 · 2023: $572 · 2024: $451 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,242 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.67 |
| Education | $228.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $649.05 | 2020-2025 | Veklury |
| Insmed, INC. | $555.19 | 2019-2025 | Arikayce |
| Paratek Pharmaceuticals, INC. | $355.43 | 2022-2023 | Nuzyra |
| Astellas Pharma US INC | $323.56 | 2022-2024 | Cresemba |
| Ferring Pharmaceuticals INC. | $292.92 | 2023-2024 | Rebyota |
| Merck Sharp & Dohme LLC | $256.91 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Viiv Healthcare Company | $200.24 | 2022-2025 | Dovato |
| Boston Scientific Corporation | $66.93 | 2024-2025 | Watchman Flx |
| Shionogi INC | $32.68 | 2025 | Fetroja |
| Mayne Pharma Commercial LLC | $28.25 | 2020-2021 | |
| Smith+Nephew, INC. | $24.09 | 2023 | Collagenase Santyl |
| Astrazeneca Pharmaceuticals LP | $20.66 | 2023 | |
| Allergan, INC. | $19.41 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $11.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellias Maroun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.